C12N 2770/24161
Methods of inactivation or attenuation
C12N2770/24161 (Methods of inactivation or attenuation) appears on 167 US grants and 212 published applications in this corpus.
Search patents in C12N- Granted patents
- 167
- Published applications
- 212
- Assignees
- 105
- Inventors
- 333
- Latest grant
- 23 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 0 |
| 2003 | 6 | 3 |
| 2004 | 4 | 6 |
| 2005 | 3 | 8 |
| 2006 | 0 | 4 |
| 2007 | 3 | 12 |
| 2008 | 6 | 7 |
| 2009 | 5 | 9 |
| 2010 | 7 | 10 |
| 2011 | 9 | 10 |
| 2012 | 7 | 8 |
| 2013 | 3 | 7 |
| 2014 | 13 | 8 |
| 2015 | 5 | 7 |
| 2016 | 6 | 4 |
| 2017 | 6 | 7 |
| 2018 | 8 | 15 |
| 2019 | 10 | 14 |
| 2020 | 13 | 14 |
| 2021 | 7 | 13 |
| 2022 | 12 | 12 |
| 2023 | 8 | 11 |
| 2024 | 12 | 12 |
| 2025 | 5 | 9 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production23 Sep 2025US 12,419,947 B2Najit Technologies, Inc.
- Virus purification and formulation process20 May 2025US 12,305,198 B2Global Life Sciences Solutions USA LLC
- Virus purification4 Feb 2025US 12,214,033 B2Valneva SE
- Development of dengue virus vaccine components21 Jan 2025US 12,203,100 B2The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
- Compositions and methods for dengue virus chimeric constructions in vaccines7 Jan 2025US 12,186,363 B2Takeda Vaccines, Inc.
- Use of dengue vaccine in pregnant and/or breastfeeding subjects23 Apr 2026US 2026/0108594 A1Takeda Vaccines, Inc.
- Combination therapy of oncolytic virus drugs for cancer treatment26 Feb 2026US 2026/0053873 A1Sichuan Oncocare Biopharmaceutical, Inc.
- Zika vaccines and immunogenic compositions, and methods of using the same18 Dec 2025US 2025/0381261 A1Takeda Vaccines, Inc.
- Chimeric zika virus anticancer vaccine obtained through breast cancer cell passage25 Sep 2025US 2025/0295750 A1
- Self-amplifying mrna vaccine based on z7 genome14 Aug 2025US 2025/0255952 A1The University of Southern Mississippi
Most cited
By later US patents
- Chimeric and/or growth-restricted flaviviruses67US 6,184,024 B2The United States of America as represented by the Department of Health and Human Services · 2001
- Chimeric west nile/dengue viruses52US 8,715,689 B2The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · 2014
- Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA50US 6,063,628 AUniversity of Washington · 2000
- Method for inactivating a virus36US 5,891,705 APentose Pharmaceuticals, Inc. · 1999
- Chimeric flavivirus vaccines35US 6,696,281 B1Acambis Inc. · 2004